All In Biotech

Drug Trial Radar · NCT06048887

Single and Multiple-Ascending Dose Study of CRN04894 in Healthy Volunteers

A Double-blind, Randomized, Placebo-controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of CRN04894 in Healthy Volunteers

Last checked: Nov 19, 2026Latest source record: Sep 21, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

88

Actual

Start

Dec 18, 2020

Primary completion

Apr 11, 2022

Study completion Apr 11, 2022

Sponsor

Lead sponsor
Crinetics Pharmaceuticals Inc.Industry
Sponsor type
Industry
First posted
Sep 21, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

A Phase 1, first-in-human, double-blind, randomized, placebo-controlled study to evaluate the safety of CRN04894 in healthy volunteers as well as the relationship between exposure and pharmacodynamic (PD) parameters.

Conditions

  • Healthy Volunteers

Interventions

  • CRN04894 Oral SolutionDrug

    CRN04894 is an orally active nonpeptide melanocortin 2 receptor (MC2R) or adrenocorticotropic hormone (ACTH) antagonist.

  • Placebo Oral SolutionDrug

    Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of subjects with treatment-emergent adverse eventsTime frame: Part 1 - up to Day 8; Part 2 - up to Day 20
  2. Proportion of participants with a clinically significant safety laboratory observationTime frame: Part 1 - up to Day 8; Part 2 - up to Day 20

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • QPS-Miami Research Associates

    Miami, Florida

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.